Sistemic announces world-first with publication on the potential for patient stratification using a cell-based therapy for refractory rheumatoid arthritis

Release Date: January 9, 2017

Sistemic Ltd. announced today the publication of its ground-breaking research, undertaken together with TiGenix, identifying a set of circulating miRNA biomarkers which could potentially be used, if further clinically validated, to stratify refractory rheumatoid arthritis patients, prior to treatment, into responders and non-responders to an allogenic cell-based therapy:

Sistemic announce new miRNA publication exploring the functional differences between MSCs derived from different tissues and the continued expansion of patent portfolio in the exosome and predictive biomarker space.

Release Date: October 5, 2016

Glasgow, Scotland. Sistemic Ltd. announced today that it has recently published, in collaboration with colleagues at Institute of Infection, Inflammation and Immunity, Glasgow Biomedical Research Centre, University of Glasgow, evidence of significant and potentially functionally relevant differences between MSCs from Olfactory Mucosa and from Bone Marrow revealed by miRNA profiling.